健康管理模板
Home
|
About Us
|
Pipeline
|
Technology
|
Media
English
中文
English
NEWS
GDB shifts SHX-021 to weekly dose
2026-02-27
GDB has decided to shift the development ofits daily oral semaglutide to a weekly oral program (SHX-021). This decision isbased on internal data demonstrating superior pharmacokinetic profiles that...
GDB’s patent application claiming the combination of GLP-1 RA and SGLT2i was published in China.
2025-01-08
GDB ispleased to announce that the patent application claiming the combination ofGLP-1 RA and SGLT2i (International Application Number PCT/CN2021/142542) enterinto the publication status in China. ...
GDB’s oral heparin patent application was published in China.
2025-01-08
GDB ispleased to announce that the oral heparin patent application (InternationalApplication Number PCT/CN2021/135770) enter into the publication status inChina. The publication date is September 1...
GDB first oral macromolecule delivery international patent application was published in China.
2025-01-08
GDB is pleased to announce that the first oral macromolecule deliveryinternational patent application (International Application NumberPCT/CN2022/126156) enter into the publication status in China....
